pp-186 Solution for infusion

Indication: Third-line (3L) non-small cell lung cancer (NSCLC) — post checkpoint inhibitor (CPI) failure Clinical stage: Phase 3 Modality: Small molecule (telomere-targeting nucleoside analogue) Mechanism / Target: First-in-class telomere-targeting nucleotide; incorporates into cancer cell telomeres generating reactive oxygen species and telomere dysfunction; triggers immunogenic cell death and stimulates anti-tumour immune response; synergises with checkpoint inhibitors Route / form: IV infusion Differentiation: First-in-class telomere-targeting NCE with dual mechanism (direct cytotoxicity + immune activation); Phase 3 THIO-104 initiated Dec 2025 for 3L NSCLC — a population with no approved standard of care; unique mechanism potentiating CPI response;